NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Precirix

Precirix

Private
BrusselsHealthcare & Life Scienceshttps://precirix.com/

Last Round

Series B

Mar 16, 2022

Total Funding Raised

$129.61M

Company Overview

Precirix is a biotechnology company that develops targeted radiopharmaceuticals for cancer therapy using camelid single-domain antibodies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

radiopharmaceuticalstargeted radionuclide therapytheranosticsnanobodiessingle-domain antibodiesprecision oncologycancer therapybiotechnologyclinical trialsdrug discoverysolid tumor treatmentbiopharmatargeted therapyradioisotope therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Precirix Comparables

Compare Precirix with similar companies based on industry and business-model similarity.

Precirix comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TwoStep Therapeutics
84%
Ariceum Therapeutics
84%
Alpha-9 Oncology
84%

Precirix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 16, 2022
GrantJan 1, 2019
Series ANov 15, 2018
SeedOct 14, 2014

Key People

Founding team and executive leadership

Tom Plitz

CEO Member Of The Board Of Directors

Executive Team

Josie Gayton

Chief Operating Officer

Executive Team

Precirix Investors

Notable investors and investment history

Precirix investors
InvestorRounds
BioMedPartnersSeries B, Series A
ForbionSeries B
GimvSeries B, Series A
Pontifax Venture CapitalSeries B, Series A
HealthCapSeries B, Series A
V-Bio VenturesSeries B, Series A
Novo HoldingsSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 16, 2022

    $88M round led by Jeito, Inkef Capital, and Forbion.

  • Jan 1, 2019

    $8.4K grant received from Innoviris.

Precirix Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Precirix Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Precirix's valuation, stock price, and market status.

Firmographic Details

HeadquartersBrussels
Employee Range10
Year Founded2014
Last FundingMar 16, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.